JP2023533030A5 - - Google Patents
Info
- Publication number
- JP2023533030A5 JP2023533030A5 JP2023501079A JP2023501079A JP2023533030A5 JP 2023533030 A5 JP2023533030 A5 JP 2023533030A5 JP 2023501079 A JP2023501079 A JP 2023501079A JP 2023501079 A JP2023501079 A JP 2023501079A JP 2023533030 A5 JP2023533030 A5 JP 2023533030A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- patients weighing
- less
- antibody
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063049768P | 2020-07-09 | 2020-07-09 | |
| US63/049,768 | 2020-07-09 | ||
| PCT/US2021/040802 WO2022011086A1 (en) | 2020-07-09 | 2021-07-08 | Dosage and administration of anti-c5 antibodies for treating paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023533030A JP2023533030A (ja) | 2023-08-01 |
| JP2023533030A5 true JP2023533030A5 (https=) | 2025-10-03 |
Family
ID=77127113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023501079A Pending JP2023533030A (ja) | 2020-07-09 | 2021-07-08 | 小児患者において発作性夜間血色素尿症（ｐｎｈ）を治療するための抗ｃ５抗体の投薬量及び投与 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230235035A1 (https=) |
| EP (2) | EP4178674A1 (https=) |
| JP (1) | JP2023533030A (https=) |
| WO (1) | WO2022011086A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3024618A1 (en) | 2016-05-27 | 2017-11-30 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| EP3802593B1 (en) | 2018-05-31 | 2024-09-11 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
| EP3873602B1 (en) | 2018-10-30 | 2023-12-06 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) |
| WO2024227120A1 (en) * | 2023-04-27 | 2024-10-31 | Alexion Pharmaceuticals, Inc. | Systems and methods for monitoring quality of life (qol) features in pnh patients treated with complement pathway inhibitors |
| WO2024229000A1 (en) * | 2023-05-02 | 2024-11-07 | Alexion Pharmaceuticals, Inc. | Pediatric dosage and administration of anti-c5 antibodies for treatment of complement disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| CN116769024A (zh) * | 2016-06-14 | 2023-09-19 | 瑞泽恩制药公司 | 抗c5抗体及其用途 |
| EP3802593B1 (en) * | 2018-05-31 | 2024-09-11 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
-
2021
- 2021-07-08 US US18/011,807 patent/US20230235035A1/en active Pending
- 2021-07-08 EP EP21748759.4A patent/EP4178674A1/en not_active Withdrawn
- 2021-07-08 JP JP2023501079A patent/JP2023533030A/ja active Pending
- 2021-07-08 EP EP23193515.6A patent/EP4295905A1/en active Pending
- 2021-07-08 WO PCT/US2021/040802 patent/WO2022011086A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023533030A5 (https=) | ||
| JP2021525718A5 (https=) | ||
| US12528859B2 (en) | Single domain serum albumin binding protein | |
| JP2022512632A5 (https=) | ||
| JP7489978B2 (ja) | 抗ＦｃＲｎ抗体を用いたグレーブス眼症の治療方法 | |
| JP2021501134A5 (https=) | ||
| JP2021526534A5 (https=) | ||
| JP2018511609A5 (https=) | ||
| JP2020536097A5 (https=) | ||
| JP2020528894A5 (https=) | ||
| WO2017064615A1 (en) | Use of c5 inhibitors in transplant associated microangiopathy | |
| JP2023533682A5 (https=) | ||
| EA014025B1 (ru) | Композиции антитела против cd3 | |
| EP3554543A2 (en) | Stable aqueous anti-c5 antibody composition | |
| RU2003126168A (ru) | Терапевтические связывающие молекулы | |
| JP2023528441A5 (https=) | ||
| TW202417482A (zh) | 治療補體介導疾病的方法 | |
| JP2023539047A5 (https=) | ||
| JP2024540435A5 (https=) | ||
| JP2018533588A (ja) | 治療パラダイム | |
| JP2023504209A5 (https=) | ||
| JP2022520572A5 (https=) | ||
| JP2025528527A (ja) | 抗ＦｃＲＮ抗体を用いたグレーブス病の治療方法 | |
| Yasuda et al. | The changes in treatment strategies in ABOi living donor liver transplantation for acute liver failure | |
| CN113993543B (zh) | 使用抗cd38抗体的组合疗法 |